Organon & Co. is set to report second-quarter earnings on Monday, with market watchers assessing whether the pharmaceutical firm can rebound from its April earnings shortfall. Analysts project adjusted earnings of 90 cents per share on revenue of $1.57 billion, representing a 9.9% year-over-year decline in earnings and a 1.3% drop in sales. The figures mark a modest sequential improvement from the prior quarter’s 71 cents per share on $1.46 billion in revenue.
The company’s performance has come under pressure following a first-quarter miss, where adjusted earnings fell 14.5% below expectations and revenue trailed estimates by 4%. Organon’s women’s health franchise, a core segment, reported a 16% revenue decline during the period. The stock, currently trading at $13.74, remains near its 52-week high of $13.76 but is down sharply from its March low of $5.69. The mean analyst price target of $11.25 implies an 18% downside, with no buy ratings among the five firms covering the stock.
A pending merger with Sun Pharmaceutical Industries, valued at $11.75 billion in an all-cash deal at $14.00 per share, adds another layer of investor focus. Shareholders approved the transaction in July, though the deal’s completion is not expected until early August, coinciding with the launch of a Risk Evaluation and Mitigation Strategy (REMS) program for Organon’s contraceptive drug Miudella. The company operates in 140 countries and markets over 70 products, including contraceptives, fertility treatments, and biosimilars.
Consensus estimates for Organon have remained unchanged over the past week and month, reflecting limited revision despite the stock’s volatility. Investors will weigh the company’s ability to stabilize its core franchises against the backdrop of the pending acquisition, which could reshape its long-term strategic direction.
